Erlizumab
Erlizumab (rhuMAb) is a monoclonal antibody against the Integrin b2/ITGB2/CD18 subunit of the Mac-1 receptor. Erlizumab can reduce reperfusion injury in myocardial infarction[1].
Product Specifications
CAS Number
211323-03-4
Product Name Alternative
RhuMAb
UNSPSC
12352203
Target
Integrin
Type
Inhibitory Antibodies
Related Pathways
Cytoskeleton
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/erlizumab.html
Purity
98.49
Smiles
[Erlizumab]
Molecular Weight
(49.293 kDa)
References & Citations
[1]Nigam A, et al. Therapeutic potential of monoclonal antibodies in myocardial reperfusion injury. Am J Cardiovasc Drugs. 2002;2 (6) :367-76.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
